Lauren Santye, Assistant Editor

Patients who received the shingles vaccine before treatment for arthritis with tofacitinib showed robust immune responses.

Cladribine tablets demonstrated sustained clinical efficacy for up to 4 years treating multiple sclerosis.

Novel technology could reduce the number of unnecessary biopsies, ultimately reducing health care costs.

Newly launched mobile research study uses real-time data collection in MS.

Texas-based pharmacies work to ensure access to lifesaving medications for patients displaced and homeless due to the flooding caused by Hurricane Harvey.

The findings highlight the role of Tregs in suppressing the immune response.

Tisagenlecleucel (Kymriah) is a personalized genetically-modified autologous T cell immunotherapy designed to use a patient’s own T cells to target and kill leukemia.

Tisagenlecleucel is indicated for pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia.

Statins may provide a protective effect against breast cancer development.

Approximately 12,000 customers were affected by the breach.

Scientists hone in on personalized treatments for patients with cancer.

Top news of the day from across the health care landscape.

An estimated 1.2 million American women would likely benefit from recommended genetic test to assess their risk of cancer.

A recently-published study evaluated increasing concerns that plaque psoriasis medications may trigger inflammatory bowel disease (IBD).

The $2 million grant seeks to help establish guidelines for further development of treatments for HIV.

FDA to evaluate obinutuzumab (Gazyva) in combination with chemotherapy for patients with previously untreated follicular lymphoma.

Fulvestrant is a hormonal therapy that targets the estrogen receptor and helps slow cancer growth.

Faslodex reduced disease progression by 20% among women with HR+, HER2- advanced breast cancer.

A decision on the approval of obinutuzumab is expected by December 23, 2017.

Use of oral contraceptives for 7 or more consecutive years associated with lower risk of rheumatoid arthritis.

Top news of the day from across the health care landscape.

Findings may lead to new targeted treatment options for HIV infection.

The program is a combination of research, health care services, and community involvement in harm reduction strategies.

The findings offer a new pathway for developing treatments for diseases such as amyotrophic lateral sclerosis.

Treatments for hepatitis C, hemophilia, and cholesterol among specialty drugs approved for new indications this year.

Women who worked the night shift found to have a greater risk of developing breast cancer.

West Virginia University program seeks to combat the spread of infectious diseases via injection drug use.

New ulcerative colitis and Crohn’s disease cases were uncommon in plaque psoriasis patients administered ixekizumab.

Top news of the day from across the health care landscape.

Study findings may improve treatment options for autoimmune disease.